Retrospective Analysis of Nephrotoxicity During Daptomycin Versus Vancomycin Treatments in High Risk Patients

CompletedOBSERVATIONAL
Enrollment

72

Participants

Timeline

Start Date

January 1, 2016

Primary Completion Date

January 30, 2016

Study Completion Date

January 30, 2016

Conditions
Infective EndocarditisInfection Related to Ventricular Assist DeviceInfection Related to Vascular ProthesisSurgical Site InfectionMediastinitis
Interventions
DRUG

Daptomycin (DAP) treatment

Group DAP : Daptomycin was administered at a dose of 8 mg/kg in thirty-minutes intravenous infusion every 24 hours in patients without severe impairment of kidney function or every 48 hours in case of GFR below 30 ml/min/m2. The creatine-kinase (CK) level was measured before the initiation of DAP and at least once a week to assess the occurrence of muscular toxicity defined by an increase of CK up to 3-fold the upper superior limit without any evidence of member ischaemia.

DRUG

Vancomycin (VAN) treatment

Group VAN : Vancomycin intravenous treatment was initiated by a loading dose of 30 mg/kg in 1 hour and followed by a continuous maintenance infusion dosing between 15 and 30 mg/kg/d. The VAN dose was adapted to achieve a target serum vancomycin steady-state concentration of 20-30 mg/L assessed by a daily pharmacologic monitoring (therapeutic drug monitoring).

Trial Locations (1)

34295

Uh Montpellier, Montpellier

All Listed Sponsors
lead

University Hospital, Montpellier

OTHER

NCT03961503 - Retrospective Analysis of Nephrotoxicity During Daptomycin Versus Vancomycin Treatments in High Risk Patients | Biotech Hunter | Biotech Hunter